Details of Disease

General Information of Disease (ID: DIS86ETN)

Disease Name	Raynaud disease
Synonyms	cold fingers, hereditary; secondary Raynaud's phenomenon; Raynaud's disease; Raynaud's syndrome (disorder) [ambiguous]; secondary Raynaud disease; Raynaud syndrome; secondary Raynaud phenomenon; Raynaud's syndrome; secondary Raynaud's disease; Raynaud disease
Disease Class	BD42: Raynaud phenomenon
Definition	An episodic vasoconstriction resulting in discoloration of the skin and pain in the affected areas, often involving fingers or toes. Classically associated with triphasic color changes (white, blue, red) but may be biphasic. Often occurs in response to cold temperatures or emotional stress. May be primary or secondary to an underlying autoimmune disease.
Disease Hierarchy	DISYKSRF: Genetic disease DISXSU1Y: Peripheral vascular disease DIS86ETN: Raynaud disease
ICD Code	ICD-11 ICD-11: BD42.0 ICD-10 ICD-10: I73.0 ICD-9 ICD-9: 443 Expand ICD-11 'BD42.0; 'BD42.1 Expand ICD-10 'I73.0 Expand ICD-9 443
Disease Identifiers	MONDO ID MONDO_0008364 MESH ID D011928 UMLS CUI C0034734 OMIM ID 179600 MedGen ID 20473 SNOMED CT ID 195295006

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)

This Disease is Treated as An Indication in 1 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Moxisylyte	DMFCLYW	Approved	Small molecular drug	[1]
------------------------------------------------------------------------------------

This Disease is Treated as An Indication in 1 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
PF-489791	DM3C8GQ	Phase 2	Small molecular drug	[2]
------------------------------------------------------------------------------------

This Disease is Treated as An Indication in 2 Discontinued Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Isoxsuprine	DMURMY1	Withdrawn from market	Small molecular drug	[3]
SLX-2101	DM1J0YB	Discontinued in Phase 2	NA	[4]
------------------------------------------------------------------------------------

This Disease is Treated as An Indication in 1 Preclinical Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
SRD-326	DMRWF1U	Preclinical	NA	[5]
------------------------------------------------------------------------------------

This Disease is Treated as An Indication in 3 Investigative Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
BC-RD-03	DMOVN93	Investigative	NA	[6]
ELS-130	DM97PYC	Investigative	NA	[6]
VPZ-758	DMA0KJN	Investigative	NA	[6]
------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)

This Disease Is Related to 2 DME Molecule(s)

Gene Name	DME ID	Evidence Level	Mode of Inheritance	REF
GSTM1	DEYZEJA	moderate	Biomarker	[7]
GSTT1	DE3PKUG	moderate	Biomarker	[7]
------------------------------------------------------------------------------------

References

1	Raynaud disease. J Hand Surg Am. 2014 Jan;39(1):121-4.
2	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800025495)
3	Sublingual and oral isoxsuprine in patients with Raynaud's phenomenon. Eur J Clin Pharmacol. 1981;20(5):329-33.
4	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800022583)
5	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800028726)
6	The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
7	Glutathione S-transferase M1 and GST T1 genetic polymorphisms and Raynaud's phenomenon in French vinyl chloride monomer-exposed workers.J Hum Genet. 2006;51(10):879-886. doi: 10.1007/s10038-006-0038-9. Epub 2006 Sep 15.